Poland· PL-100475161
Mounjaro
A tirzepatide product containing tirzepatydum, registered in Poland by Eli Lilly Nederland B.V.. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tirzepatide is registered in 15 of 19 countries.
Countries holding a registration under ATC A10BX16 (tirzepatide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Tirzepatide · ATC A10BX16
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tirzepatide costs, country by country.
Normalised to the WHO defined daily dose (1.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tirzepatide · price per daily dose (1.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$45.12
The record
At a glance
URPL (Poland)- Active substance
- Tirzepatydum
- Manufacturer
- Eli Lilly Nederland B.V.
- Country
- Poland (PL)
- ATC code
- A10BX16
- ATC class
- Tirzepatide
- Defined daily dose
- 1.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05907677973185
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tirzepatide in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMOUNJAROEli Lilly Nederland B.V., Utrecht
- SpainMOUNJARO 12,5 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAEli Lilly Nederland B.V.
- IcelandMounjaroEli Lilly Nederland B.V.*
- BelgiumMounjaro 12.5 mgEli Lilly Nederland
- SwitzerlandMounjaro 12.5 mg, solution for injection in vialEli Lilly (Suisse) SA
- SwedenMounjaro 12,5 mg Injektionsvätska, lösningEli Lilly Nederland B.V.
- United KingdomMounjaro KwikPen 7.5mg/0.6ml solution for injection 2.4ml pre-filled pensEli Lilly and Company Ltd
- United StatesMounjaroEli Lilly and Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Mounjaro, Mounjaro Kwikpen
- Liechtenstein · Mounjaro, Mounjaro Kwikpen
- Norway · Mounjaro, Mounjaro Kwikpen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/170451f7-b035-45d5-8971-083cce11ba6b GET /v1/drugs/170451f7-b035-45d5-8971-083cce11ba6b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "12,5 mg",
"packaging": "05907677973185 ¦ Rp ¦ EU/1/22/1685/023 ¦ 151590\n1 fiol. 0,5 ml\nRp ¦ EU/1/22/1685/041 ¦ 159807\n4 fiol. 0,5 ml\nRp ¦ EU/1/22/1685/043 ¦ 159808\n4 fiol. 0,5 ml (4x1) opakowanie zbiorcze\nRp ¦ EU/1/22/1685/042 ¦ 159809\n12 fiol. 0,5 ml\nRp ¦ EU/1/22/1685/044 ¦ 159810\n12 fiol. 0,5 ml (12x1) opakowanie zbiorcze",
"substance": "Tirzepatydum 12.5 mg/0.5 ml",
"common_name": "Tirzepatydum",
"pl_product_id": "100475161",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tirzepatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.